Subscribe To
SNPX / Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit
Content Topics
Synaptogenix
Present
Hanson
Wade
10th
Annual
Neurodegenerative
Development
Summit
Stock
SNPX
SNPX News
By InvestorPlace
December 16, 2022
Why Is Synaptogenix (SNPX) Stock Plummeting 70% Today?
Clinical-stage biopharmaceutical firm Synaptogenix (NASDAQ: SNPX ) demonstrated the harsh pitfalls associated with innovative medicine. Following the more_horizontal
By Seeking Alpha
December 9, 2022
Synaptogenix: Bryostatin For Alzheimer's, As Binary As Can Be
Synaptogenix has announced a readout of a Phase 2 randomized placebo-controlled trial in Alzheimer's disease for the current quarter. Preclinical work more_horizontal
By PRNewsWire
March 29, 2022
Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit
NEW YORK , March 29, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company more_horizontal
By PRNewsWire
March 22, 2022
Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum
NEW YORK , March 22, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company more_horizontal
By PRNewsWire
March 15, 2022
Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
NEW YORK , March 15, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutic more_horizontal
By Seeking Alpha
November 16, 2021
Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment
SNPX did not achieve primary endpoints in two Phase 2 studies for Bryostatin for the treatment of Alzheimer's Disease in moderately severe to severe p more_horizontal
By Seeking Alpha
November 16, 2021
Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment
SNPX did not achieve primary endpoints in two Phase 2 studies for Bryostatin for the treatment of Alzheimer's Disease in moderately severe to severe p more_horizontal
By Seeking Alpha
November 16, 2021
Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment
SNPX did not achieve primary endpoints in two Phase 2 studies for Bryostatin for the treatment of Alzheimer's Disease in moderately severe to severe p more_horizontal